

Literaturverzeichnis zum Artikel „Neues aus der Kardiologie“

von Professor Dr. Melchior Seyfarth und Professor Dr. Albert Schömig, Heft 10/2008, Seite 592-596

1. Thygesen K, Alpert JS, White HD, et al. Universal Definition of Myocardial Infarction. *Circulation* 2007;116:2634-2653.
2. Authors/Task Force M, Bassand J-P, Hamm CW, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. *Eur Heart J* 2007;28:1598-1660.
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *The Lancet* 2003;361:13-20.
4. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. *Circulation* 2008;117:296-329.
5. Hamm CW. Leitlinien der DGK: Akutes Koronarsyndrom (ACS) Teil 2: Akutes Koronarsyndrom mit ST-Hebung. *Z Kardiol* 2004;93:324-41.
6. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. *The Lancet*;367:569-578.
7. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. *N Engl J Med* 2008;358:2205-2217.
8. Investigators) MJeafB-. Abciximab in Patients with AMI Undergoing Primary PCI After Clopidogrel Pretreatment. *J Am Coll Cardiol* 2008;ACC Meeting 2008 (Late Breaking Clinical Trial).
9. Mehta SR, Cannon CP, Fox KAA, et al. Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes: A Collaborative Meta-analysis of Randomized Trials. *JAMA* 2005;293:2908-2917.
10. Neumann F-J, Kastrati A, Schwarzer G. New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective. *Eur Heart J* 2007;9:A4-A10.
11. Hausleiter J, Meyer T, Hadamitzky M, et al. Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. *Eur Heart J* 2007;28:3034-3041.
12. Hausleiter J, Meyer T, Hadamitzky M, et al. Radiation Dose Estimates From Cardiac Multislice Computed Tomography in Daily Practice: Impact of Different Scanning Protocols on Effective Dose Estimates. *Circulation* 2006;113:1305-1310.
13. Boden WE, O'Rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. *N Engl J Med* 2007;356:1503-1516.
14. Schömig A, Mehilli J, Waha Ad, Seyfarth M, Pache J, Kastrati A. A Meta-Analysis of 17 Randomized Trials of a PCI-Based Strategy in Patients With Stable Coronary Artery Disease. *J Am Coll Cardiol* in press.
15. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. *N Engl J Med* 2007;356:1030-1039.
16. Lagerqvist B, James SK, Stenestrand U, et al. Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. *N Engl J Med* 2007;356:1009-1019.
17. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. *JAMA* 2007;297:159-168.

18. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry. *Circulation* 2006;113:2803-2809.
19. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *The Lancet* 2007;370:937-948.
20. Silber S, Borggrefe M, Böhm M, et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES). *Der Kardiologe* 2007;1:84-111.
21. Nakagawa H, Jackman WM. Catheter Ablation of Paroxysmal Supraventricular Tachycardia. *Circulation* 2007;116:2465-2478.
22. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006;114:e257-354.
23. Stevenson WG, Soejima K. Catheter Ablation for Ventricular Tachycardia. *Circulation* 2007;115:2750-2760.
24. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *The Lancet* 2003;362:772-776.
25. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. *The Lancet* 2000;355:1582-1587.
26. The OI. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. *N Engl J Med* 2008;358:1547-1559.
27. Cleland JGF, Daubert J-C, Erdmann E, et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. *N Engl J Med* 2005;352:1539-1549.
28. Bax JJ, Abraham T, Barold SS, et al. Cardiac Resynchronization Therapy: Part 1--Issues Before Device Implantation. *Journal of the American College of Cardiology* 2005;46:2153-2167.
29. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous Aortic Valve Replacement for Severe Aortic Stenosis in High-Risk Patients Using the Second- and Current Third-Generation Self-Expanding CoreValve Prosthesis: Device Success and 30-Day Clinical Outcome. *Journal of the American College of Cardiology* 2007;50:69-76.
30. Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2007;116:1736-1754.